Heartflow (HTFL) vs Pulse Biosciences (PLSE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pulse Biosciences (PLSE) has outperformed Heartflow (HTFL) over the past year, gaining 150.7% versus a gain of 41.1%. Heartflow is the larger company by market cap ($4.14 billion vs $3.56 billion), about 1.2 times the size. Heartflow converts more of its revenue into profit, with a net margin of -66.3% versus -20794.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HTFL | PLSE |
|---|---|---|
| Share price | $47.63 | $49.98 |
| Market cap | $4.14B | $3.56B |
| 1-day change | -3.50% | +1.81% |
| YTD return | +69.33% | +264.02% |
| 1-year return | +41.07% | +150.65% |
| 5-year return | — | +130.85% |
| EPS (TTM) | $-0.24 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $176.03M | $350.00K |
| Revenue growth (YoY) | +39.92% | — |
| Net income (latest FY) | $-116.79M | $-72.78M |
| Gross margin | 76.80% | -54.00% |
| Operating margin | -36.39% | -21982.57% |
| Net margin | -66.35% | -20794.57% |
| 52-week high | $54.32 | $58.90 |
| 52-week low | $20.13 | $12.56 |
| Distance from 52-week high | -12.32% | -15.14% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -3.42% | +13.05% |
| Average volume | 1.79M | 502.81K |
| Shares outstanding | 86.95M | 71.32M |
| Employees | 843 | 116 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLSE has outperformed HTFL by 109.6 percentage points over the past year.
- Heartflow is more profitable, keeping -66.3 cents of every revenue dollar as net income versus -20794.6 cents for Pulse Biosciences.
About Heartflow
HTFL stock →HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries.
Health Care · Medical/Dental Instruments · 843 employees
About Pulse Biosciences
PLSE stock →Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
Health Care · Medical/Dental Instruments · 116 employees
HTFL vs PLSE FAQ
Which is bigger, Heartflow or Pulse Biosciences?
Heartflow (HTFL) is larger, with a market capitalization of $4.14B compared with $3.56B for Pulse Biosciences (PLSE).
Which stock has performed better over the past year, HTFL or PLSE?
PLSE returned +150.65% over the past 12 months, compared with +41.07% for HTFL (price return, excluding dividends). Past performance does not predict future results.
Are Heartflow and Pulse Biosciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.